Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time

• References

• 1 Linkins LA, Dans AL, Moores LK. et al. Treatment and prevention of heparin-induced thrombocy-topenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e495S-530S.
• 2 Alatri A, Armstrong AE, Greinacher A. et al. Results of a consensus meeting on the use of argatro-ban in patients with heparin-induced thrombocy-topenia requiring antithrombotic therapy - a european perspective. Thromb Res 2012; 129: 426-433.
• 3 Lewis BE, Wallis DE, Berkowitz SD. et al. Argatro-ban anticoagulant therapy in patients with hepa-rin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.
• 4 Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28: 361-368.
• 5 Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: A comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 2005; 16: 251-257.
• 6 Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007; 98: 234-242.
• 7 Warkentin TE. Anticoagulant failure in coagulo-pathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf 2014; 13: 25-43.
• 8 Guy S, Kitchen S, Maclean R. et al. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban. Int J Lab Hematol 2015; 37: 834-843.
• 9 Smythe MA, Forsyth LL, Warkentin TE. et al. Progressive, fatal thrombosis associated with heparin-induced thrombocytopenia after cardiac surgery despite Ȝtherapeutic” anticoagulation with argatro-ban: Potential role for PTT and ACT confounding. J Cardiothorac Vasc Anesth 2015; 29: 1319-1321.
• 10 Keyl C, Zimmer E, Bek MJ. et al. Argatroban phar-macokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected hepa-rin-induced thrombocytopenia. Thromb Haemost 2016; 115: 1081-1089.
• 11 Akimoto K, Klinkhardt U, Zeiher A. et al. Antico-agulation with argatroban for elective percutaneous coronary intervention: Population phar-macokinetics and pharmacokinetic-pharmacody-namic relationship of coagulation parameters. J Clin Pharmacol 2011; 51: 805-818.
• 12 Walenga JM. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb 2002; 32 (Suppl. 03) 9-14.
• 13 Gosselin RC, King JH, Janatpour KA. et al. Comparing direct thrombin inhibitors using aPTT, eca-rin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004; 38: 1383-1388.
• 14 Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-187.
• 15 Schaden E, Schober A, Hacker S. et al. Ecarin modified rotational thrombelastometry: A point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban. Wien Klin Wo-chenschr 2013; 125: 156-159.
• 16 Lind SE, Boyle ME, Fisher S. et al. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol 2014; 141: 665-674.
• 17 Curvers J, van de Kerkhof D, Stroobants AK. et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: Which assay is helpful?. Am J Clin Pathol 2012; 138: 551-558.
• 18 Wanat MA, Hart SR, Putney D. et al. Alternative monitoring of argatroban using plasma-diluted thrombin time. Ann Pharmacother 2013; 47: e18.